From the study about melanoma, the activation of β-catenin signaling reduces the numbers of intratumoral CD103+ DCs that prevent tumor-specific T cell priming and anti-tumor immunity, at the same time, CD103+ DCs are also critical target for the efficacy of immunotherapy with PD-L1 and Braf inhibition [123, 125]. The gene discussed is BRAF; the disease is neoplasm.